Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Currently, there are only two drugs for HFpEF: SGLT2 inhibitor and ARNI. The ALPK2/TPM1 regulatory axis may provide a unique therapeutic target for HFpEF, allowing the development of new treatment ...

Experts And Viewpoints, October 07, 2019 PARAGON-HF: Is There a Role for the ARNI in HFpEF? Ileana Piña quizzes investigator Burkert Pieske on the findings for sacubitril/valsartan in patients ...

Integrating GLP-1 therapies with lifestyle factors and nutrition counseling is essential for optimal outcomes in patients with HFpEF. Stay at the forefront of Med School & Residency — REGISTER ...

Recent trials have shown the effectiveness of GLP-1 therapies in reducing cardiovascular risk and improving outcomes in patients with obesity and HFpEF. These therapies have the potential to ...

The company has also received FDA approval to initiate LEVEL-2, a global Phase 3 study for TNX-103 in PH-HFpEF, with the first patient expected to be enrolled later this year. This study aims to ...